Olin Corporation
OLN
$23.81
-5.89%
Olin Corporation is a diversified chemical manufacturer operating in the Basic Materials sector, specifically within the Specialty Chemicals industry. Its core business is organized into three segments: Chlor Alkali Products and Vinyls (the largest revenue contributor), Epoxy resins, and the Winchester sporting ammunition brand. The company is a significant, established player in the North American chemical and ammunition markets, known for its integrated chlor-alkali chain and well-recognized Winchester brand. The current investor narrative centers on navigating a cyclical downturn in chemical pricing and demand, as evidenced by recent quarterly losses and revenue declines, while simultaneously managing its capital structure and positioning for a potential industry recovery.…
OLN
Olin Corporation
$23.81
Related headlines
Investment Opinion: Should I buy OLN Today?
Rating: Hold. The core thesis is that OLN presents a classic deep-value, cyclical turnaround play, but the timing of the recovery is too uncertain and the near-term fundamentals too weak to justify a Buy rating, aligning with the prevailing neutral analyst sentiment.
Supporting evidence includes an exceptionally low Price-to-Sales ratio of 0.35, suggesting the market has priced in a deep trough. The company continues to generate strong free cash flow of $247.9M TTM, providing a financial cushion. However, this is counterbalanced by severe margin erosion (Q4 gross margin 1.88%) and a net loss of -$85.7M. The forward PE of 28.70x, based on an estimated EPS of $1.44, shows the market expects a sharp rebound, creating a high bar for execution.
The thesis would upgrade to a Buy if chemical pricing shows clear signs of stabilization, evidenced by a return to positive quarterly net income or gross margins expanding sustainably above 10%. It would downgrade to a Sell if free cash flow turns negative or if the stock breaks below its 52-week low of $18.08, signaling a failed recovery. Relative to its own depressed history, the stock appears fairly valued for the current cycle phase, but it is not yet cheap enough to discount the significant execution risks.
Sign up to view all
OLN 12-Month Price Forecast
OLN is a bet on the timing of a chemical cycle turn, and the data suggests it is too early to call the bottom with high conviction. The valuation is compelling for deep-value investors, but the fundamental deterioration is real and recent. The neutral stance reflects the high uncertainty, with the balance of probabilities favoring a gradual, volatile recovery (base case) over a swift V-shaped rebound. The stance would upgrade to bullish on confirmation of margin stabilization (gross margin >10% for two consecutive quarters) and downgrade to bearish on a breakdown of the $18.08 support level coupled with negative quarterly FCF.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Olin Corporation's 12-month outlook, with a consensus price target around $30.95 and implied upside of +30.0% versus the current price.
Average Target
$30.95
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$19 - $31
Analyst target range
Analyst coverage for OLN is limited, with only 8 analysts providing estimates, which is typical for a mid-cap, cyclical industrial company. The consensus sentiment leans neutral to cautious, as evidenced by recent institutional ratings from firms like Wells Fargo (Equal Weight), Citigroup (Neutral), and Morgan Stanley (Underweight). The average EPS estimate for the coming period is $1.44, with a range from $1.17 to $1.94. However, a consensus price target and explicit Buy/Hold/Sell distribution are not available in the provided data, making an implied upside/downside calculation impossible. The pattern in recent institutional actions shows stability but no bullish conviction; all ratings changes in 2026 have been reiterations of Neutral, Market Perform, or Hold ratings, with one Underweight from Morgan Stanley. The lack of upgrades and the prevalence of neutral ratings signal that analysts are waiting for clearer signs of a fundamental turnaround before turning more positive. The wide spread in EPS estimates (a 66% range from low to high) underscores the high uncertainty surrounding the company's near-term earnings power, which is characteristic of a stock at a cyclical inflection point.
Bulls vs Bears: OLN Investment Factors
The bull and bear cases for OLN are in sharp tension, with the evidence currently leaning bearish on fundamentals but bullish on valuation and recovery potential. The bear side presents stronger near-term evidence with concrete data on collapsing margins (1.88% gross margin) and quarterly losses (-$85.7M). However, the bull case is anchored in the extreme valuation discount (PS of 0.35) and the market's forward-looking expectation of an earnings rebound (forward PE 28.70x). The single most important tension in the investment debate is the timing and magnitude of the cyclical recovery in chemical pricing. If pricing rebounds faster than expected, the deep-value setup offers substantial upside. If the downturn persists or deepens, the high leverage and ongoing losses could lead to further multiple compression and test the recent lows.
Bullish
- Extreme Valuation Discount: OLN trades at a Price-to-Sales ratio of 0.35, near the bottom of its historical range which extended above 4.0. This deep discount prices in a severe cyclical trough and offers significant upside if chemical pricing recovers, as the market currently assigns minimal value to its revenue base.
- Despite posting a net loss, the company generated $247.9 million in trailing twelve-month free cash flow. This strong cash generation provides a crucial buffer to service its debt (D/E of 1.79) and fund operations during the downturn, reducing near-term solvency risk.
- Analyst Expects Sharp Earnings Rebound: The forward P/E of 28.70x, based on an average EPS estimate of $1.44, implies the market anticipates a dramatic recovery from the current quarterly loss of -$0.75. This forward multiple reflects confidence in a cyclical upswing, with the high EPS estimate reaching $1.94.
- Technical Recovery from Lows: The stock has rallied 11.45% over the past three months and is up 24.89% over the past year, recovering from its 52-week low of $18.08. Trading at $26.09, it is 81% of the way back to its 52-week high of $30.46, indicating strong buying interest off the cyclical bottom.
Bearish
- Severe Profitability Collapse: Q4 2025 gross margin collapsed to 1.88% from 10.71% in Q3, leading to a net loss of -$85.7 million. The trailing net margin is -0.63%, confirming the company is currently unprofitable, which directly challenges the investment thesis reliant on a swift recovery.
- Revenue Decline and Cyclical Downturn: Q4 2025 revenue of $1.67B declined -0.37% YoY and sequentially from Q3's $1.71B. This confirms the company is in a downcycle for its core chemical businesses, with no near-term visibility on demand or pricing stabilization.
- High Financial Leverage: A debt-to-equity ratio of 1.79 indicates significant financial leverage. While FCF is positive, sustained losses could pressure the company's ability to comfortably manage this debt load, especially if interest rates remain elevated.
- Analyst Sentiment Cautious, No Bullish Conviction: Recent institutional ratings are Neutral (Wells Fargo, Citigroup) or Underweight (Morgan Stanley), with no upgrades in 2026. The wide EPS estimate range (66% from low to high) underscores high uncertainty and a lack of conviction in the timing of a recovery.
OLN Technical Analysis
The stock is in a pronounced recovery phase within a volatile, wide trading range. Over the past year, OLN has gained 24.89%, but this masks significant volatility, with the current price of $26.09 sitting approximately 81% of the way up from its 52-week low of $18.08 towards its high of $30.46. This positioning near the upper end of the range suggests the stock has recaptured significant lost ground but may face resistance as it approaches recent highs. Recent momentum is mixed; the stock is up 11.45% over the last three months, indicating a strong recovery leg, but has declined 0.84% over the past month, signaling a potential consolidation or pullback after the recent rally. This divergence from the strong 3-month trend suggests a pause in momentum, which is typical after a sharp move higher. Key technical levels are clearly defined by the 52-week range, with immediate support near the $18.08 low and primary resistance at the $30.46 high. A decisive breakout above $30.46 would signal a resumption of the bullish trend and potentially open the door to further gains, while a breakdown below the recent lows would indicate the recovery has failed. The stock's beta of 1.366 indicates it is approximately 37% more volatile than the broader market (SPY), which is significant for risk management as it implies larger price swings in both directions. This elevated volatility is corroborated by the stock's 1-month relative strength of -8.20% versus the SPY, showing it has recently underperformed the market during a period of broad strength.
Beta
1.17
1.17x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$18-$30
Price range past year
Annual Return
+17.3%
Cumulative gain past year
| Period | OLN Return | S&P 500 |
|---|---|---|
| 1m | -11.1% | +1.5% |
| 3m | -9.5% | +13.4% |
| 6m | +15.8% | +10.9% |
| 1y | +17.3% | +24.5% |
| ytd | +10.5% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OLN Fundamental Analysis
OLN's revenue trajectory reflects the challenges of a cyclical chemical downturn. The most recent Q4 2025 revenue was $1.67 billion, representing a slight year-over-year decline of -0.37%. More telling is the sequential trend from the stronger Q3 2025 revenue of $1.71 billion, indicating softening demand as the year progressed. Segment data shows the Chlor Alkali and Vinyls segment contributed $856.4 million, the Epoxy segment $359.3 million, and Winchester $449.4 million, though the exact period for this split is not specified. The declining revenue trend implies the company is in a downcycle, pressuring the investment case reliant on a commodity price recovery. Profitability has deteriorated sharply into negative territory. The company reported a net loss of -$85.7 million in Q4 2025, with a gross margin of a mere 1.88%, a severe compression from the 10.71% gross margin in Q3 2025. This quarterly net loss contrasts with a net income of $43.0 million in the prior quarter, highlighting extreme margin volatility and the impact of weak pricing. The trailing twelve-month net margin is -0.63%, confirming the company is currently unprofitable on an annualized basis, a significant shift from the profitability seen in earlier quarters of 2024. The balance sheet shows elevated financial leverage, with a debt-to-equity ratio of 1.79, indicating a high degree of indebtedness. However, liquidity appears adequate with a current ratio of 1.35. A critical positive is the company's ability to generate cash; trailing twelve-month free cash flow is a robust $247.9 million. This strong FCF, coupled with an ROA of 1.12% and an ROE of -2.26%, suggests the company can service its debt and fund operations internally despite the earnings downturn, providing a buffer during the cyclical low.
Quarterly Revenue
$1.7B
2025-12
Revenue YoY Growth
+0.00%
YoY Comparison
Gross Margin
+0.01%
Latest Quarter
Free Cash Flow
$247900000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OLN Overvalued?
Given the negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. OLN's trailing PS ratio is 0.35, which is exceptionally low and reflects the market's discount for a company currently posting losses. The forward-looking valuation is more challenging to pinpoint without a forward PS, but the forward PE of 28.70x implies the market expects a significant earnings recovery, creating a vast gap with the negative trailing PE of -55.77x. Comparing to industry averages is not possible with the provided data, as no sector multiples are included. However, a PS ratio of 0.35 is generally considered very low for any industrial company, suggesting the market is pricing in substantial fundamental risk or a deep cyclical trough. This discount would only be justified if the company's profitability and growth prospects are perceived to be permanently impaired relative to peers. Historically, OLN's valuation has compressed dramatically. The current PS ratio of 0.35 is near the very bottom of its observable historical range, which extended above 4.0 during the peak profitability cycle in 2021-2022. Trading at such depressed historical multiples suggests the market has priced in a severe downturn. This could represent a deep-value opportunity if the cycle turns, but it also signals that expectations for growth and margins are at a cyclical low point.
PE
-55.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -445x~499x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced. OLN's profitability has evaporated, with Q4 gross margin at 1.88% and a net loss of -$85.7 million, creating earnings risk if the chemical downcycle persists. The company carries high financial leverage with a debt-to-equity ratio of 1.79, which, while currently serviceable by its robust $247.9M TTM free cash flow, becomes a burden if FCF generation weakens. Revenue concentration in cyclical chlor-alkali and epoxy markets exposes the company to volatile commodity pricing, with Q4 revenue already showing sequential decline.
Market & Competitive Risks center on valuation and macro sensitivity. Trading at a forward PE of 28.70x implies a steep earnings recovery is priced in; failure to deliver could trigger significant multiple compression. The stock's beta of 1.366 indicates it is 37% more volatile than the market, amplifying downside during sector-wide selloffs. Competitive pressures in commodity chemicals could delay margin recovery, while the Winchester segment, though defensive, operates in a competitive and potentially regulated ammunition market.
Worst-Case Scenario involves a prolonged chemical downturn coupled with a broader market correction. In this adverse scenario, quarterly losses deepen, free cash flow turns negative, and the high debt load triggers credit rating concerns. The stock could re-test and break below its 52-week low of $18.08, representing a downside of approximately -31% from the current price of $26.09. A drawdown of this magnitude is plausible given the stock's historical max drawdown of -31.45% and its high volatility profile.
FAQ
The key risks are, in order of severity: 1) Cyical & Profitability Risk: The core chemical business is in a downturn, with Q4 gross margin at 1.88% and quarterly losses; a prolonged slump is the primary threat. 2) Financial Leverage Risk: A debt-to-equity ratio of 1.79 amplifies losses and could become burdensome if free cash flow weakens. 3) Valuation & Volatility Risk: The stock's high beta of 1.366 leads to larger price swings, and the forward PE of 28.7x sets a high bar—missing it could cause a sharp decline. 4) Execution & Sentiment Risk: Analyst sentiment is neutral/cautious; failure to show sequential improvement could lead to downgrades and further derating.
The 12-month forecast is highly scenario-dependent due to OLN's cyclical nature. Our base case (50% probability) sees a range of $26-$30, implying modest upside as the company gradually returns to profitability. The bull case (30% probability) targets $30.46-$35 on a swift chemical recovery and strong execution. The bear case (20% probability) warns of a retest of the $18.08 low if the downturn deepens. The most likely outcome is the base case—a choppy, volatile recovery within the established trading range, with the stock's path dictated by quarterly margin trends rather than a smooth upward trajectory.
OLN is deeply undervalued on a historical and asset-based perspective but fairly valued or even overvalued on a forward-earnings basis, creating a paradox. The trailing Price-to-Sales ratio of 0.35 is near the bottom of its historical range, suggesting the market is assigning minimal value to its revenue stream. However, the forward P/E of 28.70x implies the market is already pricing in a significant earnings recovery to an estimated $1.44 EPS. Therefore, the stock is undervalued only if you believe the earnings rebound will be stronger and sooner than currently expected. The current valuation reflects deep skepticism about near-term profits.
OLN is a high-risk, high-potential-reward stock that is only a good buy for a specific type of investor. For deep-value, contrarian investors with a long time horizon and high risk tolerance, the extreme valuation discount (PS ratio of 0.35) and strong free cash flow ($247.9M TTM) present a compelling setup. However, for most investors, it is not a good buy due to the severe near-term profitability collapse (Q4 net loss of -$85.7M), high debt (D/E 1.79), and lack of a clear near-term catalyst. The stock is a bet on a chemical cycle recovery whose timing is highly uncertain.
OLN is strictly a long-term investment for investors with a minimum 2-3 year horizon. This is a cyclical turnaround story that requires time for industry conditions to improve, margins to recover, and debt to be managed down. The stock's high volatility (beta 1.366) and lack of a reliable dividend (payout ratio negative) make it unsuitable for short-term trading or income investors. The deep-value opportunity only materializes if the cycle turns, which is a multi-quarter process. Attempting to trade OLN short-term is akin to speculating on commodity prices, which is exceptionally difficult.